Navigation Links
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
Date:9/3/2008

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence anti-HAAH monoclonal antibody covered under this patent, as a cancer therapeutic antibody drug and anticipates the start of Phase 1 clinical trials in early 2009.

HAAH is a cancer molecular marker that has been detected by immunohistochemical staining in a broad range of cancers; this marker was originally discovered at the Rhode Island Hospital / Brown University. Research done both at Panacea and in collaboration with Brown University / Rhode Island Hospital has established HAAH as an excellent drug target for cancer therapy as well as a marker for cancer diagnosis. HAAH over-expression has been observed in more than twenty different cancers, and HAAH has been shown to be highly specific for cancer and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals. In cancer, HAAH is found on the cell surface and in normal cells found in minute quantities inside the cell. As such, HAAH is an excellent therapeutic target. Panacea has demonstrated the efficacy of PAN-622, an all-human sequence anti-HAAH monoclonal antibody, in animal models of cancer. In these experiments PAN-622 inhibited tumor growth in 90 percent of animals, with 40 percent showing no visible tumor. Tumors did not re-grow beyond the period of drug administration. Due to its all human sequence, PAN-622 is anticipated to have low toxicity in humans. And PAN-622 is currently being manufactured under cGMP at high yields.
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 2011 Reportlinker.com announces that a new market research ... Pain Therapeutics - Drugs, Markets and Companies ... report describes the latest concepts of pathomechanisms of pain ... pharmacotherapies for pain. Major segments of the pain market ...
... Pharmacotherapy research is set to become vastly more ... Wolters Kluwer Pharma Solutions , parent of the ... scientific information and analytics to professionals in the pharmaceutical and ... access (OA) publishing option for authors submitting original research articles ...
Cached Medicine Technology:Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 2Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 3Adis Journals Embrace Open Access 2Adis Journals Embrace Open Access 3Adis Journals Embrace Open Access 4
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
(Date:4/23/2014)... Using frozen stool from healthy, unrelated donors was ... relapsing diarrhea caused by Clostridium difficile , ... Clinical Infectious Diseases and available online. ... equally effective whether given via a colonoscope or ... may make this promising treatment more readily available ...
(Date:4/23/2014)... to give exercise enthusiasts the extra nudge they need ... a cyber buddy can help. , The study, which ... is the first to indicate that although a human ... software-generated partner also can be effective. , "We wanted ... motivate people to give greater effort while exercising than ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... be the cause, experts say , WEDNESDAY, May 26 (HealthDay ... older person,s condition. , The joint disease occurs over time ... allowing the bones to rub together and causing pain, swelling ... it,s like death and taxes -- you will likely get ...
... ... new member to its Board of Directors. The announcement was made by Jim Clarke, founder and ... ... a new member to its Board of Directors. The announcement was made by Jim Clarke, founder ...
... ... to health and beauty PR agency Robin Leedy & Associates (RL&A), helping to develop ... ... and beauty PR specialists Robin Leedy & Associates (RL&A) , a niche brand ...
... ... of their latest product Performance Canvas 2.2 as a mobile analytics ... 2.2 with Planning, the first fully unified Information Synthesis, Performance Management ... Sharepoint 2010 and SQL Analysis Services R2. The Performance Canvas Mobile ...
... ... are proud to team with the L.A. Dodger,s ThinkCure organization for "YAS-A-THON for ThinkCure," ... ... Fowler and her YAS Fitness Centers are proud to team with the L.A. Dodger,s ...
... ... Jones will take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle ... retirement and VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be ...
Cached Medicine News:Health News:Osteoarthritis Claims Growing Number of Younger Victims 2Health News:Osteoarthritis Claims Growing Number of Younger Victims 3Health News:2 BigHearts Board Announces Addition to Board of Directors: Michael Unetich 2Health News:Robin Leedy & Associates Hires Digital Content Producer, Taking Social Media for Drugstore Brands Digital Capability to the Next Level 2Health News:Robin Leedy & Associates Hires Digital Content Producer, Taking Social Media for Drugstore Brands Digital Capability to the Next Level 3Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:REBEL WITH A CAUSE: Kimberly Fowler and YAS Fitness Centers Roll with L.A. Dodgers to Cure Cancer 2Health News:REBEL WITH A CAUSE: Kimberly Fowler and YAS Fitness Centers Roll with L.A. Dodgers to Cure Cancer 3Health News:VGM Insurance President Passes the Baton 2
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
... Proven Knee System is a long term, ... design. Available in both posterior stabilized and ... Knee System provides the flexibility needed to ... and ease of identification keeps the user ...
... FluoroNav Virtual Fluoroscopy software ... Technologies has incorporated ease ... technology features such as ... three-dimensional models of image ...
... T.L.I.F. SG Instruments are the next evolution ... comprehensive and functionally sound instruments.. The T.L.I.F. ... disc removal and disc preparation instruments designed ... Excellent design, a wide range of instrument ...
Medicine Products: